EGFR and squamous cell carcinoma: Expanding upon this with updated data and additional studies, we found that adjuvant ICI therapy significantly prolonged DFS—particularly in EGFR-negative, PD-L1 (1–49%), non-squamous carcinoma, or never-smokers—it did not improve OS in completely resected stage IB–III NSCLC.